233 related articles for article (PubMed ID: 15382266)
21. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I.
Suttorp M; Claviez A; Bader P; Peters C; Gadner H; Ebell W; Dilloo D; Kremens B; Kabisch H; Führer M; Zintl F; Göbel U; Klingebiel T
Klin Padiatr; 2009; 221(6):351-7. PubMed ID: 19890786
[TBL] [Abstract][Full Text] [Related]
22. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
[TBL] [Abstract][Full Text] [Related]
23. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Suttorp M
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S40-6. PubMed ID: 18978743
[TBL] [Abstract][Full Text] [Related]
24. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
26. Treatment options for newly diagnosed patients with chronic myeloid leukemia.
Maness LJ; McSweeney PA
Curr Hematol Rep; 2004 Jan; 3(1):54-61. PubMed ID: 14695851
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Kim YJ; Kim DW; Lee S; Kim YL; Hwang JY; Park YH; Kim HJ; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2004 Jan; 33(2):237-42. PubMed ID: 14628081
[TBL] [Abstract][Full Text] [Related]
28. First-Line management of CML: a state of the art review.
Hochhaus A
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
[TBL] [Abstract][Full Text] [Related]
29. Chronic myelogenous leukaemia (CML): an update.
Kumar L
Natl Med J India; 2006; 19(5):255-63. PubMed ID: 17203680
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
[TBL] [Abstract][Full Text] [Related]
31. Role of allogeneic transplantation in chronic myeloid leukemia.
Heim D; Gratwohl A
Expert Rev Hematol; 2008 Oct; 1(1):41-50. PubMed ID: 21083006
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
33. [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
Fischer T
Med Klin (Munich); 2002 Jan; 97 Suppl 1():22-7. PubMed ID: 11831068
[TBL] [Abstract][Full Text] [Related]
34. Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.
Maziarz RT; Mauro MJ
Bone Marrow Transplant; 2003 Sep; 32(5):459-69. PubMed ID: 12942091
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia.
Radich JP; Olavarria E; Apperley JF
Hematol Oncol Clin North Am; 2004 Jun; 18(3):685-702, x. PubMed ID: 15271400
[TBL] [Abstract][Full Text] [Related]
36. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
37. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
[TBL] [Abstract][Full Text] [Related]
38. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
39. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
[TBL] [Abstract][Full Text] [Related]
40. Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?
Liang Y; Lai Y; Schwarzenberger P; Li Q; Ma J; Luo J; Liu R; Shi L; Zhou J; Peng Z; Yang J; Deng D; Zhou Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):848-53. PubMed ID: 20138227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
